Company: Altus Pharmaceuticals [1]
Starting stock price: $19.19
Ending stock price: $5.18
Percent Change: -73.01%
Details: In July Altus lost orphan drug status for its experimental pancreatic insufficiency therapy; the FDA said the number of patients with the condition exceeds the 200,000 mark required for an orphan drug. But the real blow came in December when Genentech return the North American rights to ALTU-238, a growth hormone. Altus is looking for another partner for the drug.
More News:
Altus shares dive as Genentech hands back drug rights. Report [2]
Altus loses orphan drug status. Report [3]
Altus inks $140M pact for human growth hormone. Report [4]
Altus stock plunges on clinical trial delay. Report [5]
Links:
[1] http://www.altus.com/news-and-events/press-detail.cfm?id=16
[2] http://www.fiercebiotech.com/story/altus-shares-dive-genentech-hands-back-drug-rights/2007-12-20
[3] http://www.fiercebiotech.com/story/altus-loses-orphan-drug-status/2007-07-05
[4] http://www.fiercebiotech.com/story/altus-inks-140m-pact-for-human-growth-hormone/2006-12-20
[5] http://www.fiercebiotech.com/story/altus-stock-plunges-on-clinical-trial-delay/2006-07-25
[6] http://www.fiercepharma.com/special-reports/acusphere-worst-pharma-stocks-2007
[7] http://www.fiercepharma.com/special-reports/worst-pharma-stocks-2007
[8] http://www.fiercepharma.com/special-reports/artes-medical-worst-pharma-stocks-2007